Lazarus Response to Selpercatinib for Bleeding Colic Metastasis in a Patient With RET Fusion-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report.

In recent years, the widespread use of next-generation sequencing (NGS) allowed clinicians to identify and treat non-small cell lung cancer (NSCLC) efficiently with target therapy. RET inhibitors, like selpercatinib and pralsetinib, for RET rearrangements in lung cancer showed high efficacy and clinical benefit. Nevertheless, to date, the use of molecular-targeted agents has not been tested in all lung cancer subtypes. Indeed, pulmonary sarcomatoid carcinoma (PSC) remains a rare form of NSCLC, unresponsive to standard chemotherapy, and associated with extremely poor prognosis. We report the first case of a patient affected by RET fusion-positive PSC with a bleeding colic metastasis and a consequent poor performance status who achieved a dramatic response to selpercatinib and a remarkable clinico-radiological benefit.

Informations de copyright

Copyright © 2024, Monaca et al.

Déclaration de conflit d'intérêts

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Giampaolo Tortora declare(s) non-financial support from BMS. Advisory board member. Giampaolo Tortora declare(s) non-financial support from Novartis. Advisory board member. Emilio Bria declare(s) Speaker and travel fee from MSD. Emilio Bria declare(s) Speaker and travel fee from Pfizer. Emilio Bria declare(s) a grant and speaker and travel fee from Astra-Zeneca. Emilio Bria declare(s) a grant and speaker and travel fee from Roche. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.